TY - JOUR T1 - Measurement properties of the ASAS Health Index: results of a global study in patients with axial and peripheral spondyloarthritis JF - Annals of the Rheumatic Diseases JO - Ann Rheum Dis SP - 1311 LP - 1317 DO - 10.1136/annrheumdis-2017-212076 VL - 77 IS - 9 AU - Uta Kiltz AU - Désirée van der Heijde AU - Annelies Boonen AU - Nurullah Akkoc AU - Wilson Bautista-Molano AU - Ruben Burgos-Vargas AU - James Cheng-Chung Wei AU - Praveena Chiowchanwisawakit AU - Maxime Dougados AU - M Tuncay Duruoz AU - Bassel Kamal Elzorkany AU - Inna Gaydukova AU - Lianne S Gensler AU - Michele Gilio AU - Simeon Grazio AU - Jieruo Gu AU - Robert D Inman AU - Tae-Jong Kim AU - Victoria Navarro-Compan AU - Helena Marzo-Ortega AU - Salih Ozgocmen AU - Fernando Pimentel dos Santos AU - Michael Schirmer AU - Simon Stebbings AU - Filip E Van den Bosch AU - Astrid van Tubergen AU - Juergen Braun Y1 - 2018/09/01 UR - http://ard.bmj.com/content/77/9/1311.abstract N2 - Objectives To evaluate construct validity, interpretability, reliability and responsiveness as well as determination of cut-off points for good and poor health within the original English version and the 18 translations of the disease-specific Assessment of Spondyloarthritis international Society Health Index (ASAS HI) in 23 countries worldwide in patients with spondyloarthritis (SpA).Methods A representative sample of patients with SpA fulfilling the ASAS classification criteria for axial (axSpA) or peripheral SpA was used. The construct validity of the ASAS HI was tested using Spearman correlation with several standard health outcomes for axSpA. Test–retest reliability was assessed by intraclass correlation coefficients (ICCs) in patients with stable disease (interval 4–7 days). In patients who required an escalation of therapy because of high disease activity, responsiveness was tested after 2–24weeks using standardised response mean (SRM).Results Among the 1548 patients, 64.9% were men, with a mean (SD) age 42.0 (13.4) years. Construct validity ranged from low (age: 0.10) to high (Bath AnkylosingSpondylitisFunctioning Index: 0.71). Internal consistency was high (Cronbach’s α of 0.93). The reliability among 578 patients was good (ICC=0.87 (95% CI 0.84 to 0.89)). Responsiveness among 246 patients was moderate-large (SRM=−0.44 for non-steroidal anti-inflammatory drugs, −0.69 for conventional synthetic disease-modifying antirheumatic drug and −0.85 for tumour necrosis factor inhibitor). The smallest detectable change was 3.0. Values ≤5.0 have balanced specificity to distinguish good health as opposed to moderate health, and values ≥12.0 are specific to represent poor health as opposed to moderate health.Conclusions The ASAS HI proved to be valid, reliable and responsive. It can be used to evaluate the impact of SpA and its treatment on functioning and health. Furthermore, comparison of disease impact between populations is possible. ER -